Clinical trials: Moderate to Severe Asthma
Asthma
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe asthma.
- Trial name
- NCT07436221
- Testing
- AK139
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Akeso
Asthma Bronchiale
An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma
Flutiform® compared with the individual components Flixotide® (Fluticasone) and Foradil® (Formoterol) in adolescent and adult patients.
- Trial name
- NCT00563056
- Testing
- Flutiform, Flixotide plus Foradil
- Where
- 6 sites in Germany, Hungary and 4 more
- Volunteers
- 227 people
- Sponsor
- Mundipharma Research Limited
Asthma
VENTURI (VENTilation Using Respiratory Imaging)
The purpose of the study is to enroll participants with uncontrolled asthma to evaluate the large and small airways and drug delivery utilizing two study drugs: Beclometasone dipropionate/Formoterol fumarate…
- Trial name
- VENTURI (NCT07282886)
- Testing
- Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Asthma
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.
- Trial name
- TRAILHEAD (NCT04673630)
- Testing
- Tezepelumab
- Where
- 6 sites in Hungary, South Africa and 1 more
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Asthma
Asthma Exacerbation Study
Asthma is a clinical syndrome that is well recognized by health care practitioners, yet asthma pathogenesis still remains poorly understood.
- Trial name
- NCT00853411
- Testing
- prednisone
- Sponsor
- University of Pittsburgh
Asthma
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
- Trial name
- NCT00219323
- Testing
- Omalizumab
- Where
- Japan
- Volunteers
- 133 people
- Sponsor
- Novartis
Moderate to Severe Asthma
A Phase Ib Study of RC1416 Injection
This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RC1416 injection in patients with moderate to severe asthma.
- Trial name
- NCT06911866
- Testing
- RC1416
- Where
- 16 sites in China
- Volunteers
- 40 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Asthma
Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
Study D9181C00001 is a Phase II, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of MEDI3506 in adult participants…
- Trial name
- FRONTIER-3 (NCT04570657)
- Testing
- MEDI3506
- Where
- 65 sites in United States, Argentina and 5 more
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Asthma
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
The purpose of this study is to provide safety and tolerability, pharmacokinetics and immunogenicity data for multiple CSJ117 doses inhaled once daily compared with placebo, in adult asthma participants treated with medium or…
- Trial name
- NCT04946318
- Testing
- CSJ117
- Where
- 58 sites in United States, Argentina and 12 more
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
- Trial name
- NCT06376045
- Testing
- Rocatinlimab
- Where
- 154 sites in United States, Argentina and 17 more
- Volunteers
- 317 people
- Sponsor
- Amgen
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Moderate to Severe Asthma
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
- Trial name
- NCT05851443
- Testing
- povorcitinib, ICS-LABA
- Where
- 82 sites in United States, Argentina and 5 more
- Volunteers
- 247 people
- Sponsor
- Incyte Corporation
Asthma
Withania Somnifera for Moderate-to-Severe Persistent Asthma
This randomized, double-blind, placebo-controlled study evaluated Withania somnifera root powder as a complementary therapy in adults with moderate-to-severe persistent asthma receiving standard asthma treatment.
- Trial name
- WISTA (NCT07787507)
- Testing
- Withania somnifera Root Powder, Standard Asthma Treatment
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Aligarh Muslim University
Moderate to Severe Allergic Asthma
Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma
The study was designed to collect data about inadequately controlled moderate to severe allergic asthma in subjects 6 to < 12 years of age, managed in a real-world setting.
- Trial name
- NCT01362621
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 474 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
Cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with persistent asthma
- Trial name
- NCT01070524
- Testing
- CHF 5188 pMDI, Budesonide extrafine pMDI, Seretide(r) Evohaler(r)
- Where
- United Kingdom
- Volunteers
- 113 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Intrinsic Asthma, Allergic Asthma
The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children
The aim of investigator´s clinical trial is to investigate 52 patients aged three to five years with viral-induced asthma and 52 patients aged three to five years with allergic asthma.
- Conditions
- Intrinsic Asthma, Allergic Asthma, Allergy, Bronchial Hyperresponsiveness
- Trial name
- BHR (NCT01144910)
- Testing
- methacholine challenge test
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
Asthma
Asthma and Quantifying Delivery Of Radio Labeled Aerosol
Introduction: Inhalation therapy has been established as an efficient route to treat asthma exacerbations, but coupled to noninvasive ventilation (NIV) remains quite challenging.
- Trial name
- NCT01823926
- Testing
- Noninvasive ventilation, Jet nebulizer, The vibrating mesh nebulizer (VMN)
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- Universidade Federal de Pernambuco
Asthma
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma.
- Trial name
- NCT00818454
- Testing
- Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
- Where
- 41 sites in United States
- Volunteers
- 226 people
- Sponsor
- Boehringer Ingelheim
Moderate to Severe Asthma
A Study of CM310 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT05761028
- Testing
- CM310
- Where
- China
- Volunteers
- 600 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Moderate to Severe Asthma
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
Purpose: This study aims to improve asthma care by helping clinicians at community health centers prescribe a guideline-recommended treatment called SMART (Single Maintenance and Reliever Therapy).
- Trial name
- CHEST (NCT07241117)
- Testing
- Implementation bundle
- Where
- 7 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Washington University School of Medicine